By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.


Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


New COPD drug given marketing authorisation

The European Commission has licensed umeclidinium (Incruse) as a once-daily, maintenance bronchodilator treatment to relieve the symptoms of chronic obstructive pulmonary disease.

The long-acting muscarinic antagonist comes in a 55mcg strength inhalation powder and is intended to be delivered with the Ellipta inhaler.

Manufacturer GlaxoSmithKline said it expected that the first launches of the drug would have taken place in Europe by the end of 2014.

Readers' comments (1)

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!